Search research articles
Contact Us
Filters
Showing results (21-30 of 33) with videos related to
Page
of 4
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 10, 2019
Synergistic Effect of a Mesothelin-Targeted <sup>227</sup>Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models
Katrine Wickstroem, Urs B Hagemann, Véronique Cruciani, et al.
Journal of Medicinal Chemistry
|
July 15, 2021
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer
Ulrich Lücking, Dirk Kosemund, Niels Böhnke, et al.
Journal of Medicinal Chemistry
|
December 13, 2002
Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors
Paul W Manley, Pascal Furet, Guido Bold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 16, 2018
Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors <i>In Vitro</i> and <i>In Vivo</i>
Gerhard Siemeister, Anne Mengel, Amaury E Fernández-Montalván, et al.
Molecular Cancer Therapeutics
|
February 3, 2016
Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
Antje M Wengner, Gerhard Siemeister, Marcus Koppitz, et al.
Molecular Cancer Therapeutics
|
October 5, 2019
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models
Antje M Wengner, Gerhard Siemeister, Ulrich Lücking, et al.
Cancer Research
|
July 3, 2008
Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone
Jens Hoffmann, Ilio Vitale, Bernd Buchmann, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 27, 2019
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction
Roman C Hillig, Brice Sautier, Jens Schroeder, et al.
Journal of Medicinal Chemistry
|
August 24, 2021
BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies
Markus Berger, Lars Wortmann, Philipp Buchgraber, et al.
Journal of Medicinal Chemistry
|
June 6, 2020
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models
Ulrich Lücking, Lars Wortmann, Antje M Wengner, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 33) with videos related to
Sort By:
Page
of 4
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 10, 2019
Synergistic Effect of a Mesothelin-Targeted <sup>227</sup>Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models
Katrine Wickstroem, Urs B Hagemann, Véronique Cruciani, et al.
Journal of Medicinal Chemistry
|
July 15, 2021
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer
Ulrich Lücking, Dirk Kosemund, Niels Böhnke, et al.
Journal of Medicinal Chemistry
|
December 13, 2002
Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors
Paul W Manley, Pascal Furet, Guido Bold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 16, 2018
Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors <i>In Vitro</i> and <i>In Vivo</i>
Gerhard Siemeister, Anne Mengel, Amaury E Fernández-Montalván, et al.
Molecular Cancer Therapeutics
|
February 3, 2016
Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
Antje M Wengner, Gerhard Siemeister, Marcus Koppitz, et al.
Molecular Cancer Therapeutics
|
October 5, 2019
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models
Antje M Wengner, Gerhard Siemeister, Ulrich Lücking, et al.
Cancer Research
|
July 3, 2008
Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone
Jens Hoffmann, Ilio Vitale, Bernd Buchmann, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 27, 2019
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction
Roman C Hillig, Brice Sautier, Jens Schroeder, et al.
Journal of Medicinal Chemistry
|
August 24, 2021
BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies
Markus Berger, Lars Wortmann, Philipp Buchgraber, et al.
Journal of Medicinal Chemistry
|
June 6, 2020
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models
Ulrich Lücking, Lars Wortmann, Antje M Wengner, et al.
Page
of 4